Dr. Yerxa currently serves as Opus Genetics’ President since October, 2024. Dr. Yerxa was Chief Executive Officer and President of Opus from September, 2021. Dr. Yerxa previously served as Chief Executive Officer of the Foundation Fighting Blindness (“FFB”) starting in October 2017, a foundation that drives research to provide treatments and cures for people affected by retinal degenerative diseases, where he established the Retinal Degeneration Fund, a venture philanthropy investment fund. Prior to joining FFB, Dr. Yerxa served as President and Co-Founder of Envisia Therapeutics, Inc., a company focused on developing novel ocular sustained delivery therapies for the front and back of the eye. He also has previously held founding and executive positions in several ophthalmology-based research organizations, including Liquidia Technologies, Inc., a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension, Clearside Biomedical, Inc. (“Clearside”), a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space, Parion Sciences, Inc., a company that develops therapies to treat defects of the innate mucosal defense system in respiratory diseases, and Inspire Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing ophthalmic products. Dr. Yerxa has also served on the boards of directors of Clearside since March 2022 and Nacuity Pharmaceuticals, Inc., a clinical-stage leader in innovative treatments for oxidative stress since October 2019. Dr. Yerxa holds 60 U.S. patents. Dr. Yerxa earned his Ph.D. in organic chemistry from the University of California, Irvine, and his B.A. in chemistry from the University of California, San Diego.
What is Benjamin R. Yerxa's net worth?
The estimated net worth of Benjamin R. Yerxa is at least $3.64 million as of April 23rd, 2026. Yerxa owns 711,535 shares of Opus Genetics stock worth more than $3,635,944 as of April 30th. This net worth estimate does not reflect any other investments that Yerxa may own. Learn More about Benjamin R. Yerxa's net worth.
How do I contact Benjamin R. Yerxa?
Has Benjamin R. Yerxa been buying or selling shares of Opus Genetics?
Over the course of the past ninety days, Benjamin R. Yerxa has sold $39,142.80 in shares of Opus Genetics stock. Most recently, Benjamin R. Yerxa sold 7,470 shares of the business's stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $5.24, for a transaction totalling $39,142.80. Following the completion of the sale, the president now directly owns 711,535 shares of the company's stock, valued at $3,728,443.40. Learn More on Benjamin R. Yerxa's trading history.
Who are Opus Genetics' active insiders?
Are insiders buying or selling shares of Opus Genetics?
During the last year, Opus Genetics insiders bought shares 2 times. They purchased a total of 164,000 shares worth more than $323,890.00. During the last year, insiders at the sold shares 11 times. They sold a total of 4,073,395 shares worth more than $8,982,278.31. The most recent insider tranaction occured on April, 23rd when President Benjamin R Yerxa sold 7,470 shares worth more than $39,142.80. Insiders at Opus Genetics own 11.7% of the company.
Learn More about insider trades at Opus Genetics. Information on this page was last updated on 4/23/2026.
